Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Dec 1;39(4):272-274.
doi: 10.4274/tjh.galenos.2022.2022.0290. Epub 2022 Oct 17.

Proteomic Case Studies of MDS in Progression: Heterogeneity and More Heterogeneity

Klara Pecankova  1 , Jaroslav Cermak  1 , Pavel Majek  1
Affiliations

Proteomic Case Studies of MDS in Progression: Heterogeneity and More Heterogeneity

Klara Pecankova et al. Turk J Haematol. .
No abstract available

Keywords: Myelodysplastic syndrome; Plasma proteome; Proteomics.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: No conflict of interest was declared by the authors.

References

    1. Ogawa S. Genetic basis of myelodysplastic syndromes. Proc Japan Acad Ser B Phys Biol Sci. 2020;96:107–121. - PMC - PubMed
    1. Nagata Y, Maciejewski JP. The functional mechanisms of mutations in myelodysplastic syndrome. Leukemia. 2019;33:2779–2794. - PMC - PubMed
    1. Májek P, Reicheltová Z, Suttnar J, Cermák J, Dyr JE. Plasma proteome changes associated with refractory cytopenia with multilineage dysplasia. Proteome Sci. 2011;9:64. - PMC - PubMed
    1. Májek P, Reicheltová Z, Suttnar J, Cermák J, Dyr JE. Plasma protein alterations in the refractory anemia with excess blasts subtype 1 subgroup of myelodysplastic syndrome. Proteome Sci. 2012;10:31. - PMC - PubMed
    1. Majek P, Riedelova-Reicheltova Z, Suttnar J, Pecankova K, Cermak J, Dyr JE. Proteome changes in the plasma of myelodysplastic syndrome patients with refractory anemia with excess blasts subtype 2. Dis Markers. 2014;2014:178709. - PMC - PubMed